Vicente Planelles, PhD

Research Interests

  • HIV/AIDS
  • Viral Latency
  • Apoptosis
  • Cell Cycle
  • Viral Accessory Proteins

Languages

  • English
  • French
  • Spanish

Academic Information

  • Departments: Pathology - Professor
  • Divisions: Microbiology and Immunology

Academic Office Information

  • 801-581-8655
  • School of Medicine
    Pathology
    30 N 1900 E, Room: 5C 210
    Salt Lake City, UT 84132

Email: vicente.planelles@path.utah.edu

Academic Bio

Vicente Planelles, PhD, is a Professor in the Department of Pathology at the University of Utah and a member of the Cell Response and Regulation Program at Huntsman Cancer Institute.

A major goal of his research is to understand, at a molecular level, the events that lead to apoptosis, the normal process of cell death. In cancer, cells do not die normally.

Planelles earned a bachelor's degree from the Universidad Complutense, Spain, and a PhD from the University of California, Davis.

Education History

Type School Degree
Postdoctoral Fellowship UCLA School of Medicine, Laboratory of Dr. Irvin Chen
Hematology-Oncology
Postdoctoral Fellow
Doctoral Training University of California
Immunology and Virology
Ph.D.
Graduate Training Universidad Complutense
Plant Physiology
M.S.
Undergraduate Universidad Complutense
Biological Sciences
B.S.

Global Impact

Education History

Type School Degree Country
Graduate Training Universidad Complutense
Plant Physiology
M.S. Spain
Undergraduate Universidad Complutense
Biological Sciences
B.S. Spain

Selected Publications

Journal Article

  1. Szaniawski MA, Spivak AM, Cox JE, Catrow JL, Hanley T, Williams ESCP, Tremblay MJ, Bosque A, Planelles V (2018 May 15). SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition.LID - e00819-18 [pii]LID - 10.1128/mBio.00819-18 [doi]. mBio, 9(3).
  2. Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genesca M, Castellvi J, Wu G, Del Rio Estrada PM, Gonzalez-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Teran G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ (2018 Apr 18). CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.LID - eaar6759 [pii]LID - 10.1126/scitranslmed.aar6759 [doi]. Sci Transl Med, 10(437).
  3. Planelles V (2017 Jun 3). When DNA damage is acceptable. Cell Cycle, 16(11), 1020-1021.
  4. Davis ZB, Sowrirajan B, Cogswell A, Ward JP, Planelles V, Barker E (2017 Feb). CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells. AIDS Res Hum Retroviruses, 33(2), 93-100.
  5. Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V (2017 Jan 31). Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep, 18(5), 1324-1334.
  6. Larson EC, Novis CL, Martins LJ, Macedo AB, Kimball KE, Bosque A, Planelles V, Barrows LR (2017). Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro. PLoS ONE, 12(9), e0185162.
  7. Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, Planelles V (2016 Dec 20). Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology, 13(1), 88.
  8. Larson EC, Pond CD, Szaniawski MA, Martins LJ, Planelles V, Barrows LR (2016 Dec). Macrophage Cell Coinfected with HIV-1 and H37Ra. AIDS Res Hum Retroviruses, 32(12), 1171-1172.
  9. White CH, Moesker B, Beliakova-Bethell N, Martins LJ, Spina CA, Margolis DM, Richman DD, Planelles V, Bosque A, Woelk CH (2016 Nov). Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model. PLoS Pathog, 12(11), e1006026.
  10. Sunshine S, Kirchner R, Amr SS, Mansur L, Shakhbatyan R, Kim M, Bosque A, Siliciano RF, Planelles V, Hofmann O, Ho Sui S, Li JZ (2016 May). HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol, 90(9), 4511-4519.
  11. Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC, Planelles V, Morris KV, Weinberg MS (2016 Mar). Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Mol Ther, 24(3), 488-98.
  12. Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Trypsteen W, Bosque A, Vanderkerckhove L, Planelles V (2016 Feb). Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses, 32(2), 187-93.
  13. Davis ZB, Cogswell A, Scott H, Mertsching A, Boucau J, Wambua D, Le Gall S, Planelles V, Campbell KS, Barker E (2016 Feb). A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathog, 12(2), e1005421.
  14. Garrido C, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, Planelles V, Margolis DM (2016). HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Front Immunol, 7, 356.
  15. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V (2015 Oct). Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother, 59(10), 5984-91.
  16. Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, Konig R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK (2015 Sep 9). BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe, 18(3), 345-53.
  17. Planelles V (2015 Aug 18). An Ounce of Tat Prevention Is Worth a Pound of Functional Cure.LID - 10.1128/mBio.01269-15 [doi]LID - e01269-15 [pii]. mBio, 6(4).
  18. Ramirez PW, DePaula-Silva AB, Szaniawski M, Barker E, Bosque A, Planelles V (2015 Jul 28). HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins. Retrovirology, 12, 65.
  19. DePaula-Silva AB, Cassiday PA, Chumley J, Bosque A, Monteiro-Filho CMR, Mahon CS, Cone KR, Krogan N, Elde NC, Planelles V (2015 Mar). Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm Vpr. Virology, 477, 10-17.
  20. Cassiday PA, DePaula-Silva AB, Chumley J, Ward J, Barker E, Planelles V (2014 Dec 10). Understanding the molecular manipulation of DCAF1 by the lentiviral accessory proteins Vpr and Vpx. Virology, 476C, 19-25.
  21. Murry JP, Godoy J, Mukim A, Swann J, Bruce JW, Ahlquist P, Bosque A, Planelles V, Spina CA, Young JA (2014 Dec). Sulfonation pathway inhibitors block reactivation of latent HIV-1. Virology, 471-473, 1-12.
  22. Ramirez PW, Famiglietti M, Sowrirajan B, DePaula-Silva AB, Rodesch C, Barker E, Bosque A, Planelles V (2014 Jun 26). Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4(+) T cells. Cell Rep, 7(6), 2019-30.
  23. Saayman S, Ackley A, Turner AM, Famiglietti M, Bosque A, Clemson M, Planelles V, Morris KV (2014 Jun). An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription. Mol Ther, 22(6), 1164-75.
  24. Duverger A, Wolschendorf F, Anderson JC, Wagner F, Bosque A, Shishido T, Jones J, Planelles V, Willey C, Cron RQ, Kutsch O (2014 Jan). Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol, 88(1), 364-76.
  25. Bonczkowski P, De Spiegelaere W, Bosque A, White CH, Van Nuffel A, Malatinkova E, Kiselinova M, Trypsteen W, Witkowski W, Vermeire J, Verhasselt B, Martins L, Woelk CH, Planelles V, Vandekerckhove L (2014). Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs. Retrovirology, 11, 70.
  26. Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF (2014). Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother, 58(4), 1977-86.
  27. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE, Zhou MM, Siliciano RF, Weinberger L, Verdin E, Ott M (2013 Feb 1). BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle, 12(3), 452-62.
  28. Sherrill-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocwieja KE, Berry CC, Looney D, Shan L, Agosto LM, Pace MJ, Siliciano RF, ODoherty U, Guatelli J, Planelles V, Bushman FD (2013). HIV latency and integration site placement in five cell-based models. Retrovirology, 10, 90.
  29. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V (2013). An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog, 9(12), e1003834.
  30. Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, Margolis DM, Planelles V, Bosque A (2013). Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1/2 stimulation. Retrovirology, 10, 119.
  31. Budhiraja S, Famiglietti M, Bosque A, Planelles V, Rice AP (2013 Jan). Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol, 87(2), 1211-20.
  32. Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O (2012 Apr). Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-kappaB activity. J Virol, 86(8), 4548-58.
  33. Planelles V (2012 Feb 16). SAMHD1 Joins the red Queen's court. Cell Host Microbe, 11(2), 103-5.
  34. de Silva S, Planelles V, Wu L (2012). Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells. PLoS ONE, 7(5), e35385.
  35. Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V (2011 Oct). Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog, 7(10), e1002288.
  36. Planelles V (2011 Sep). Restricted access to myeloid cells explained. Viruses, 3(9), 1624-33.
  37. Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, Planelles V, Barker E (2010 Nov 18). Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe, 8(5), 397-409.
  38. Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, Brunetta E, Mavilio D, Planelles V, Barker E (2009 Oct). HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog, 5(10), e1000613.
  39. Rosenstiel PE, Chan J, Snyder A, Planelles V, DAgati VD, Klotman PE, Klotman ME (2009 Sep 24). HIV-1 Vpr activates the DNA damage response in renal tubule epithelial cells. AIDS, 23(15), 2054-6.
  40. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E (2009 Jun). Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog, 5(6), e1000495.
  41. Bosque A, Planelles V (2009 Jan 1). Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood, 113(1), 58-65.
  42. Jacquot G, Le Rouzic E, Maidou-Peindara P, Maizy M, Lefrere JJ, Daneluzzi V, Monteiro-Filho CM, Hong D, Planelles V, Morand-Joubert L, Benichou S (2009). Characterization of the molecular determinants of primary HIV-1 Vpr proteins: impact of the Q65R and R77Q substitutions on Vpr functions. PLoS ONE, 4(10), e7514.
  43. Rosenstiel PE, Gruosso T, Letourneau AM, Chan JJ, LeBlanc A, Husain M, Najfeld V, Planelles V, DAgati VD, Klotman ME, Klotman PE (2008 Oct). HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells. Kidney Int, 74(8), 1049-58.
  44. DeHart JL, Bosque A, Harris RS, Planelles V (2008 Sep). Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol, 82(18), 9265-72.
  45. Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, Dewhurst S, Kim B (2008). Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology, 5, 11.
  46. Andjelic CD, Planelles V, Barrows LR (2008). Characterizing the anti-HIV activity of papuamide A. Mar Drugs, 6(4), 528-49.
  47. Chugh P, Fan S, Planelles V, Maggirwar SB, Dewhurst S, Kim B (2007 Feb 9). Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol, 366(1), 67-81.
  48. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V (2007). HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J, 4, 57.
  49. Andersen JL, DeHart JL, Zimmerman ES, Ardon O, Kim B, Jacquot G, Benichou S, Planelles V (2006 Dec). HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog, 2(12), e127.
  50. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V (2006 Nov). Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol, 80(21), 10407-18.
  51. Choudhary SK, Walker RM, Powell DM, Planelles V, Walsh C, Camerini D (2006 Sep 1). CXCR4 tropic human immunodeficiency virus type 1 induces an apoptotic cascade in immature infected thymocytes that resembles thymocyte negative selection. Virology, 352(2), 268-84.
  52. Dykes C, Wang J, Jin X, Planelles V, An DS, Tallo A, Huang Y, Wu H, Demeter LM (2006 Jun). Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture. J Clin Microbiol, 44(6), 1930-43.
  53. Ardon O, Zimmerman ES, Andersen JL, DeHart JL, Blackett J, Planelles V (2006 Apr). Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr. J Virol, 80(8), 3694-700.
  54. Zeng L, Planelles V, Sui Z, Gartner S, Maggirwar SB, Dewhurst S, Ye L, Nerurkar VR, Yanagihara R, Lu Y (2006 Jan). HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1. J Gene Med, 8(1), 18-28.
  55. Pang J, Cheng M, Haire SE, Barker E, Planelles V, Blanks JC (2006). Efficiency of lentiviral transduction during development in normal and rd mice. Mol Vis, 12, 756-67.
  56. Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL, Zempolich KA (2006 Jan 1). Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res, 12(1), 250-6.
  57. Lai M, Zimmerman ES, Planelles V, Chen J (2005 Dec). Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol, 79(24), 15443-51.
  58. Tripp A, Banerjee P, Sieburg M, Planelles V, Li F, Feuer G (2005 Nov). Induction of cell cycle arrest by human T-cell lymphotropic virus type 1 Tax in hematopoietic progenitor (CD34+) cells: modulation of p21cip1/waf1 and p27kip1 expression. J Virol, 79(22), 14069-78.
  59. Andersen JL, Zimmerman ES, DeHart JL, Murala S, Ardon O, Blackett J, Chen J, Planelles V (2005 Apr). ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis. Cell Death Differ, 12(4), 326-34.
  60. Dehart JL, Andersen JL, Zimmerman ES, Ardon O, An DS, Blackett J, Kim B, Planelles V (2005 Feb). The ataxia telangiectasia-mutated and Rad3-related protein is dispensable for retroviral integration. J Virol, 79(3), 1389-96.
  61. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B (2004 Dec 3). Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem, 279(49), 51545-53.
  62. Renda MJ, Bradel-Tretheway B, Planelles V, Bambara RA, Dewhurst S (2004 Dec). Inhibition of HIV type 1 replication using lentiviral-mediated delivery of mutant tRNA(Lys3)A58U. AIDS Res Hum Retroviruses, 20(12), 1324-34.
  63. Zimmerman ES, Chen J, Andersen JL, Ardon O, Dehart JL, Blackett J, Choudhary SK, Camerini D, Nghiem P, Planelles V (2004 Nov). Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol, 24(21), 9286-94.
  64. Dykes C, Balakrishnan M, Planelles V, Zhu Y, Bambara RA, Demeter LM (2004 Sep 1). Identification of a preferred region for recombination and mutation in HIV-1 gag. Virology, 326(2), 262-79.
  65. Lu Y, Liu C, Zeng L, Lin Z, Dewhurst S, Gartner S, Planelles V (2003 Nov). Efficient gene transfer into human monocyte-derived macrophages using defective lentiviral vectors. Cell Mol Biol, 49(7), 1151-6.
  66. Anderson J, Banerjea A, Planelles V, Akkina R (2003 Aug). Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses, 19(8), 699-706.
  67. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V (2003 Jul 11). Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem, 278(28), 25879-86.
  68. Zhu Y, Planelles V (2003). A multigene lentiviral vector system based on differential splicing. Methods Mol Med, 76, 433-48.
  69. Zhu Y, Roshal M, Li F, Blackett J, Planelles V (2003 Jan). Upregulation of survivin by HIV-1 Vpr. Apoptosis, 8(1), 71-9.
  70. Planelles V (2003). Hybrid lentivirus vectors. Methods Mol Biol, 229, 273-84.
  71. Yin G, Liu W, An P, Li P, Ding I, Planelles V, Schwarz EM, Min W (2002 May). Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther, 5(5 Pt 1), 547-54.
  72. Renda MJ, Rosenblatt JD, Klimatcheva E, Demeter LM, Bambara RA, Planelles V (2001 Oct). Mutation of the methylated tRNA(Lys)(3) residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1. J Virol, 75(20), 9671-8.
  73. Zhu Y, Feuer G, Day SL, Wrzesinski S, Planelles V (2001 Oct). Multigene lentiviral vectors based on differential splicing and translational control. Mol Ther, 4(4), 375-82.
  74. Klimatcheva E, Planelles V, Day SL, Fulreader F, Renda MJ, Rosenblatt J (2001 Jun). Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol Ther, 3(6), 928-39.
  75. Pandya S, Boris-Lawrie K, Leung NJ, Akkina R, Planelles V (2001 May 1). Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system. Hum Gene Ther, 12(7), 847-57.
  76. Zhu Y, Gelbard HA, Roshal M, Pursell S, Jamieson BD, Planelles V (2001 Apr). Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. J Virol, 75(8), 3791-801.
  77. Wrzesinski S, Seguin R, Liu Y, Domville S, Planelles V, Massa P, Barker E, Antel J, Feuer G (2000 Nov 1). HTLV type 1 Tax transduction in microglial cells and astrocytes by lentiviral vectors. AIDS Res Hum Retroviruses, 16(16), 1771-6.
  78. Toy EP, Rodriguez-Rodriguez L, McCance D, Ludlow J, Planelles V (2000 Jan). Induction of cell-cycle arrest in cervical cancer cells by the human immunodeficiency virus type 1 viral protein R. Obstet Gynecol, 95(1), 141-6.
  79. Dreyer K, Kallas EG, Planelles V, Montefiori D, McDermott MP, Hasan MS, Evans TG (1999 Nov 20). Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses, 15(17), 1563-71.
  80. Shostak LD, Ludlow J, Fisk J, Pursell S, Rimel BJ, Nguyen D, Rosenblatt JD, Planelles V (1999 Aug 25). Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res, 251(1), 156-65.
  81. White SM, Renda M, Nam NY, Klimatcheva E, Zhu Y, Fisk J, Halterman M, Rimel BJ, Federoff H, Pandya S, Rosenblatt JD, Planelles V (1999 Apr). Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol, 73(4), 2832-40.
  82. Kutubuddin M, Federoff HJ, Challita-Eid PM, Halterman M, Day B, Atkinson M, Planelles V, Rosenblatt JD (1999 Jan 15). Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood, 93(2), 643-54.
  83. Challita-Eid PM, Klimatcheva E, Day BT, Evans T, Dreyer K, Rimel BJ, Rosenblatt JD, Planelles V (1998 Dec 20). Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein. AIDS Res Hum Retroviruses, 14(18), 1617-24.
  84. Challita-Eid PM, Abboud CN, Morrison SL, Penichet ML, Rosell KE, Poles T, Hilchey SP, Planelles V, Rosenblatt JD (1998 Oct 1). A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol, 161(7), 3729-36.
  85. LaCasse RA, Follis KE, Moudgil T, Trahey M, Binley JM, Planelles V, Zolla-Pazner S, Nunberg JH (1998 Mar). Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J Virol, 72(3), 2491-5.
  86. Lu Y, Planelles V, Li X, Palaniappan C, Day B, Challita-Eid P, Amado R, Stephens D, Kohn DB, Bakker A, Fay P, Bambara RA, Rosenblatt JD (1997 Jun 6). Inhibition of HIV-1 replication using a mutated tRNALys-3 primer. J Biol Chem, 272(23), 14523-31.
  87. Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, Chen IS (1996 Apr). Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol, 70(4), 2516-24.
  88. Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS (1996 Apr). High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol, 70(4), 2581-5.
  89. Masuda T, Planelles V, Krogstad P, Chen IS (1995 Nov). Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol, 69(11), 6687-96.
  90. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS (1995 Oct). The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol, 69(10), 6304-13.
  91. Planelles V, Bachelerie F, Jowett JB, Haislip A, Xie Y, Banooni P, Masuda T, Chen IS (1995 Sep). Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol, 69(9), 5883-9.
  92. Planelles V, Haislip A, Withers-Ward ES, Stewart SA, Xie Y, Shah NP, Chen IS (1995 Aug). A new reporter system for detection of retroviral infection. Gene Ther, 2(6), 369-76.
  93. Jamieson BD, Aldrovandi GM, Planelles V, Jowett JB, Gao L, Bloch LM, Chen IS, Zack JA (1994 Jun). Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol, 68(6), 3478-85.
  94. Giavedoni LD, Planelles V, Haigwood NL, Ahmad S, Kluge JD, Marthas ML, Gardner MB, Luciw PA, Yilma TD (1993 Jan). Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol, 67(1), 577-83.
  95. Haigwood NL, Misher L, Chin SM, Blair M, Planelles V, Scandella CJ, Steimer KS, Gardner MB, Yilma T, Hirsch VM, et al (1992 Feb-May). Characterization of group specific antibodies in primates: studies with SIV envelope in macaques. J Med Primatol, 21(2-3), 82-90.
  96. van Kuyk RW, Acevedo RA, Torres JV, Levy NB, Planelles V, Munn RJ, Unger RE, Gardner MB, Luciw PA (1991 Nov). Characterization of rhesus macaque B-lymphoblastoid cell lines infected with simian type D retrovirus. AIDS Res Hum Retroviruses, 7(11), 899-909.
  97. Planelles V, Haigwood NL, Marthas ML, Mann KA, Scandella C, Lidster WD, Shuster JR, Van Kuyk R, Marx PA, Gardner MB, et al (1991 Nov). Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. AIDS Res Hum Retroviruses, 7(11), 889-98.
  98. Legaz ME, Pedrosa MM, Martinez P, Planelles V (1990). Purification and some kinetic properties of several arginases from the lichen Evernia prunastri. Endocytobio Cell Res, 7, 73-84.
  99. Legaz ME, Pedrosa MM, Martinez P, Planelles V (1990). The effects of lichen phenols on the reaction modes of arginases produced in the light by the lichen Evernia prunastri. Endocytobio Cell Res, 7, 85-96.
  100. Planelles V, Legaz E (1987). Purification and some properties of the secreted arginase of the lichen Evernia prunastri and its regulation by usnic acid. Plant Sci, 51, 9-16.

Review

  1. Spivak AM, Planelles V (2018 Jan 29). Novel Latency Reversal Agents for HIV-1 Cure. [Review]. Annu Rev Med, 69, 421-436.
  2. Spivak AM, Planelles V (2016 Jan). HIV-1 Eradication: Early Trials (and Tribulations). [Review]. Trends Mol Med, 22(1), 10-27.
  3. Planelles V, Wolschendorf F, Kutsch O (2011 Dec 1). Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs. [Review]. Curr HIV Res, 9(8), 568-78.
  4. Bosque A, Planelles V (2011 Jan). Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. [Review]. Methods, 53(1), 54-61.
  5. Planelles V, Barker E (2010 Oct). Roles of Vpr and Vpx in modulating the virus-host cell relationship. [Review]. Mol Aspects Med, 31(5), 398-406.
  6. Planelles V, Benichou S (2009). Vpr and its interactions with cellular proteins. [Review]. Curr Top Microbiol Immunol, 339, 177-200.
  7. Andersen JL, Le Rouzic E, Planelles V (2008 Aug). HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. [Review]. Exp Mol Pathol, 85(1), 2-10.
  8. Dehart JL, Planelles V (2008 Feb). Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation. [Review]. J Virol, 82(3), 1066-72.
  9. Lama J, Planelles V (2007). Host factors influencing susceptibility to HIV infection and AIDS progression. [Review]. Retrovirology, 4, 52.
  10. Andersen JL, Planelles V (2005 Jan). The role of Vpr in HIV-1 pathogenesis. [Review]. Curr HIV Res, 3(1), 43-51.
  11. Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz R, Rossi JJ, Zaia JA (). Current Status of the Use of Gene Delivery to Treat HIV/AIDS. [Review]. Mol Ther, 11, 823-42.
  12. Barker E, Planelles V (2003 May 1). Vectors derived from the human immunodeficiency virus, HIV-1. [Review]. Front Biosci, 8, d491-510.
  13. Roshal M, Zhu Y, Planelles V (2001 Feb-Apr). Apoptosis in AIDS. [Review]. Apoptosis, 6(1-2), 103-16.
  14. Pandya S, Klimatcheva E, Planelles V (2001 Jan). Lentivirus and foamy virus vectors: novel gene therapy tools. [Review]. Expert Opin Biol Ther, 1(1), 17-40.
  15. Klimatcheva E, Rosenblatt JD, Planelles V (1999 Jun 1). Lentiviral vectors and gene therapy. [Review]. Front Biosci, 4, D481-96.
  16. Ferreira OC Jr, Planelles V, Rosenblatt JD (1997 Jun). Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. [Review]. Blood Rev, 11(2), 91-104.
  17. Gardner M, Yamamoto J, Marthas M, Miller C, Jennings M, Rosenthal A, Luciw P, Planelles V, Yilma T, Giavedoni L, et al (1992 Aug). SIV and FIV vaccine studies at UC Davis: 1991 update. [Review]. AIDS Res Hum Retroviruses, 8(8), 1495-8.
  18. Luciw PA, Shaw KE, Unger RE, Planelles V, Stout MW, Lackner JE, Pratt-Lowe E, Leung NJ, Banapour B, Marthas ML (1992 Mar). Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). [Review]. AIDS Res Hum Retroviruses, 8(3), 395-402.

Book Chapter

  1. Planelles V (). Regulatory proteins and virus replication. In Jay Levy (Ed.), HIV and the Pathogenesis of AIDS (2nd). ASM Press.
  2. Barker E, Planelles V (2003). Vectors derived from the human immunodeficiency virus, HIV-1. In Dornburg R (Ed.), Engineered Retroviruses. Austin, TX: Landes Bioscience.
  3. Planelles V (2003). Hybrid Lentivirus Vectors. In Federico M (Ed.), Lentivirus Gene Engineering Protocols. Totowa, NJ: Humana Press.
  4. Zhu Y, Planelles V (2003). A multigene lentiviral vector system based on differential splicing. Virus vectors for gene therapy: methods and protocols. In Machida C (Ed.), Virus Vectors for Gene Therapy. Molecular Medicine Series. Totowa, NJ: Humana Press, Inc.
  5. Rimel BJ, Rosenblatt JD, Planelles V (1998). HTLV-II. In Webster RG, Granoff A (Eds.), Encyclopedia of Virology. London: Academic Press Ltd.
  6. Planelles V, Li Q-X, Chen ISY (1993). The molecular basis for cell tropism in HIV. In Cullen BR (Ed.), Molecular Biology of Human Retroviruses (pp. 17-48). Oxford: Oxford University Press.
  7. Planelles V, Giavedoni L, Marthas M, Ahmad S, Scandella CJ, Luciw PA, Yilma T, Marx P, Lackner A, Gardner MB, Haigwood NL (1992). Vaccine studies with SIVmac1A11 recombinant gp130: Lack of protection from SIVmac251 challenge. In Brown F, Chanock RM, Ginsberg HS, Lerner RA (Eds.), Vaccines 92: Modern Approaches to New Vaccines Including the Prevention of AIDS (pp. 123-129). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.

Letter

  1. Camerini D, Planelles V, Chen IS (1994 May 20). CD26 antigen and HIV fusion? [Letter to the editor]. Science, 264(5162), 1160-1; discussion 1162-5.